Starpax Biopharma

09/26/2024

An innovative cancer treatment for solid tumours
A Canadian Cancer Society-awarded project has discovered an innovative cancer therapy using bacteria and magnetism which is being further developed by a Montreal-based company.

A CCS-awarded project has discovered an innovative cancer therapy using bacteria and magnetism which is being further developed by a Montreal-based company.

08/07/2024

Our COO is pleased to present at the TEN Capital Network Life Science Syndicate.

Date and time: Wednesday, August 7, from 4 to 5:30 p.m. EDT

Register for free: https://lnkd.in/ebUA4Hqk

The TEN Life Science Syndicate is a network of physicians and other healthcare professionals interested in investing in early and growth-stage companies in the life science, medical device, digital healthcare, and biotech spaces.

07/01/2024

Starpax will be presenting it's groundbreaking technology and business model at the next TEN Capital Network Syndicate.
Watch our explainer video: https://vimeo.com/903799454/07bb7e72f9

Wednesday, July 10th, at 4:00 PM ET / 1:00 PM PT.
Register Now: https://lnkd.in/gRsN7cWy

Investor Panelists: Michael Schmanske, Chief Investment Officer at AngelMD, and Franklin Rice, Executive Advisor and Strategic Advisor of Pescadero Capital Advisors

The TEN Life Science Syndicate is a network of physicians and other healthcare professionals who want to invest in early and growth-stage companies in the Life Science, Medical Device, Digital Healthcare, and Biotech spaces.

*** Investing is now opened to general public ***
USA: https://investors.starpaxbiopharma.com/
Canada: https://www.frontfundr.com/starpaxbiopharma

06/29/2024

We are thrilled to share that Sunday July 7, a Starpax team will be cycling 86km next week-end to raise funds for the Segal Cancer Center at the Jewish General Hospital (JGH). https://youtu.be/witdcCv1fN8

WE CAN ALL MAKE A DIFFERENCE IN THE FIGHT AGAINST CANCER.

Our company is committed to developing a new groundbreaking cancer treatment for solid tumors and our clinical trials will be conducted at the JGH, making this cause incredibly important to us.

This marks our third year participating in this amazing event, and we're reaching out to make this our most impactful ride yet. Every donation, no matter how big or small, brings us one step closer to better treatments and hope for countless patients and their families.

Click the link below to donate and show your support. Together, we can make a difference! 💪❤️

https://secure.jghfoundation.org/site/TR/SignatureEvents/Weekend_2024?team_id=3560&pg=team&fr_id=1210

06/29/2024

Nous sommes ravis de vous annoncer que dimanche 7 juillet, une équipe Starpax roulera 86 km à vélo afin d'amasser des fonds pour le Centre du cancer Segal de l'Hôpital général juif (HGJ) dans le cadre du Week-end 2024 pour combattre le cancer (https://youtu.be/gKYNkPlUwjo)

ENSEMBLE, NOUS AVONS LE POUVOIR DE FAIRE AVANCER LA LUTTE CONTRE LE CANCER.

Notre entreprise s’est engagée dans le développement d'un nouveau traitement anticancéreux révolutionnaire pour les tumeurs solides et nos essais cliniques seront menés à l’HGJ, ce qui rend cette cause extrêmement importante pour nous.

Cette année marque notre troisième participation à cet événement, et nous vous invitons à soutenir cette noble cause en faisant un don pour en maximiser l'impact! Chaque contribution, petite ou grande, nous rapproche un peu plus de traitements meilleurs et d'un espoir pour d'innombrables patients et leurs familles.
Cliquez sur le lien ci-dessous pour faire un don et montrer votre soutien. Ensemble, nous pouvons faire la différence! 💪❤️

https://secure.jghfoundation.org/site/TR/SignatureEvents/Weekend_2024?team_id=3560&pg=team&fr_id=1210&s_locale=fr_CA

06/27/2024

Starpax Biopharma Never-Before-Seen and Technology Transform Treatment (https://vimeo.com/903799454/07bb7e72f9)

New 27,000-square-foot manufacturing facility now in operation to produce therapeutic Magnetodrones

In a significant stride for cancer treatment, Starpax Biopharma Inc. unveiled its Starpax Cancer Treatment Platform™, a groundbreaking innovation that marks a monumental achievement in the company's journey towards pioneering new frontiers in . With a 100% remission rate and no meaningful side effects in all the subjects of the company's preclinical trials, this technology is conceived to address , representing 90% of cancer and 89% of deaths.

https://www.prnewswire.com/news-releases/starpax-biopharma-never-before-seen-magnetodrones-and-polartrak-technology-transform-cancer-treatment-302181096.html

Investing now opened to public!
USA: https://investors.starpaxbiopharma.com/
Canada: https://www.frontfundr.com/starpaxbiopharma

06/25/2024

Investment Now Opened to Canadian and International Investors.
Be part of the Starpax journey offering new hope in the fight against cancer!
¸Visit our investment page on FrontFundr https://www.frontfundr.com/starpaxbiopharma

L'investissement est désormais ouvert aux investisseurs canadiens et internationaux.
Faites partie de l'aventure Starpax pour offrir un nouvel espoir dans la lutte contre le cancer !
Visitez notre page d'investissement sur FrontFundr
https://www.frontfundr.com/starpaxbiopharma

Starpax has developed a game changing cancer treatment

05/22/2024

Starpax Biopharma is excited to share some fantastic news with you. Mr. Business Magazine recently unveiled its special edition on Life Sciences and features Starpax on the cover as, "The Best Company Leading the Cancer Fight."

You can access the article through the following link:

Starpax Biopharma Inc. is a firm creating this future with continuous dedication toward saving lives. Led by Michael Gareau (Founding President), it is a company waging war on cancer with a revolutionary weapon – Virtual Monopole Magnetic Field (VMMF) technology.

03/21/2024

We had a lovely visit from friends at Starpax!
Mr. Dan Gabay and Mr. Jean-Francois Miron from the CIUSSS West Island (Lakeshore General Hospital, St. Mary's Hospital Centre, LaSalle Hospital and more).
A fresh breeze of innovation blows through this institution, constantly seeking new ideas, emerging technologies, and innovative methods to enhance health and social care services.

Nous avons eu de la belle visite d'amis de Starpax
MM Dan Gabay et Jean-Francois Miron du CIUSSS Ouest de L’Ile de Montréal (Hôpital général du Lakeshore, Centre hospitalier de St. Mary, Hôpital de LaSalle et bien plus).
Un vent d’innovation souffle sur cette organisation constamment à la recherche de nouvelles idées, de technologies émergentes et de méthodes novatrices pour améliorer les services de santé et de soins sociaux.

12/21/2023

During this special time of the year, we wish you a Happy Holiday Season and a wonderful 2024 year with health and happiness.

En cette période spéciale de l'année, nous vous souhaitons un Joyeux temps des fêtes et une merveilleuse année 2024 remplie de santé et de bonheur.

11/29/2023

Breaking Barriers: Transformative Cancer Therapeutics, Development of the Starpax New Cancer Treatment Modality.

We were delighted to co-present with Gerald Batist about our fruitful collaboration with the Jewish General Hospital at the McGill Centre for Translational Research in Cancer event "Cancer Translational Research Horizon’’.

Highlights of the event:

🔹 Immerse yourself in the world of cutting-edge health technologies
🔹 Gain insights from leading experts in the field
🔹 Discover the latest innovations and trends shaping the future of healthcare
🔹 Network with like-minded professionals who share your passion for health technologies to forge new partnerships.

Please use the link below to register: https://lnkd.in/ezS45Pst

Thank you to Dr. Miriam Dutra, COO MCTRC, for the invitation and to the organizing team of this great event.

11/29/2023

Congratulations to Linearis Labs & Ventures for the oppening of its New Laboratory Offering an AI Biomarkers Analytical Platform for Innovation Against Cancer, Diabetes, Antimicrobial Resistance, and Other Metabolic Diseases.

We look forward to partnering with you.

, ,

Leveraging artificial intelligence (AI), Linearis provides a comprehensive health status based on the analysis of 1,400 metabolomic biomarkers through mass spectrometry. The platform will enable its clients to improve prevention, screening, treatment monitoring, and new drug discovery. Québec, Cana...